United Therapeutics Corporation Increase (Decrease) in Accrued Liabilities
United Therapeutics Corporation (UTHR) reported Increase (Decrease) in Accrued Liabilities of $7.54 million for the 6-month period ending 2013-06-30, per its 10-Q filed 2013-07-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2013-07-25
- United Therapeutics Corporation increase (decrease) in accrued liabilities for the quarter ending 2013-06-30 was $11.58M, a 34.16% increase year-over-year.
- United Therapeutics Corporation increase (decrease) in accrued liabilities for the quarter ending 2013-03-31 was -$4.03M, a 540.87% decline year-over-year.
- United Therapeutics Corporation increase (decrease) in accrued liabilities for the quarter ending 2012-12-31 was -$15.70M, a 149.64% decline year-over-year.
- United Therapeutics Corporation increase (decrease) in accrued liabilities for the quarter ending 2012-09-30 was $20.56M.
- United Therapeutics Corporation increase (decrease) in accrued liabilities for fiscal 2012 was $14.40M, a 300.64% increase from fiscal 2011.
- United Therapeutics Corporation increase (decrease) in accrued liabilities for fiscal 2011 was $3.60M, a 85.96% decline from fiscal 2010.
- United Therapeutics Corporation increase (decrease) in accrued liabilities for fiscal 2010 was $25.61M, a 178.30% increase from fiscal 2009.
- United Therapeutics Corporation increase (decrease) in accrued liabilities for fiscal 2009 was $9.20M, a 152.76% increase from fiscal 2008.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2013-06-30 | $11.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $7.54M 10-Q · filed 2013-07-25 | -$8.16M derived: sum of 3 quarters · filed 2013-07-25 | $12.40M derived: sum of 4 quarters · filed 2013-07-25 |
| 2013-03-31 | -$4.03M 10-Q · filed 2013-04-25 | -$19.74M derived: sum of 2 quarters · filed 2013-04-25 | $825.00K derived: sum of 3 quarters · filed 2013-04-25 | $9.45M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-12-31 | -$15.70M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $4.86M derived: sum of 2 quarters · filed 2013-02-26 | $13.49M derived: sum of 3 quarters · filed 2013-07-25 | $14.40M 10-K · filed 2013-02-26 |
| 2012-09-30 | $20.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $29.19M derived: sum of 2 quarters · filed 2013-07-25 | $30.11M 10-Q · filed 2012-11-01 | $61.74M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-06-30 | $8.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $9.54M 10-Q · filed 2013-07-25 | $41.17M derived: sum of 3 quarters · filed 2013-07-25 | $2.98M derived: sum of 4 quarters · filed 2013-07-25 |
| 2012-03-31 | $915.00K 10-Q · filed 2013-04-25 | $32.55M derived: sum of 2 quarters · filed 2013-04-25 | -$5.65M derived: sum of 3 quarters · filed 2013-04-25 | $3.10M derived: sum of 4 quarters · filed 2013-04-25 |
| 2011-12-31 | $31.63M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$6.56M derived: sum of 2 quarters · filed 2013-02-26 | $2.19M derived: sum of 3 quarters · filed 2013-02-26 | $3.60M 10-K · filed 2013-02-26 |
| 2011-09-30 | -$38.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$29.45M derived: sum of 2 quarters · filed 2012-11-01 | -$28.04M 10-Q · filed 2012-11-01 | -$17.75M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $8.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $10.16M 10-Q · filed 2012-07-26 | $20.44M derived: sum of 3 quarters · filed 2013-02-26 | $24.09M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $1.41M 10-Q · filed 2012-04-26 | $11.69M derived: sum of 2 quarters · filed 2013-02-26 | $15.34M derived: sum of 3 quarters · filed 2013-02-26 | $24.11M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | $10.29M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $13.93M derived: sum of 2 quarters · filed 2013-02-26 | $22.70M derived: sum of 3 quarters · filed 2013-02-26 | $25.61M 10-K · filed 2013-02-26 |
| 2010-09-30 | $3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $12.41M derived: sum of 2 quarters · filed 2011-10-27 | $15.33M 10-Q · filed 2011-10-27 | $18.35M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-06-30 | $8.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $11.69M 10-Q · filed 2011-07-28 | $14.71M derived: sum of 3 quarters · filed 2012-02-28 | $17.67M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-03-31 | $2.91M 10-Q · filed 2011-04-28 | $5.93M derived: sum of 2 quarters · filed 2012-02-28 | $8.90M derived: sum of 3 quarters · filed 2012-02-28 | |
| 2009-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $5.98M derived: sum of 2 quarters · filed 2012-02-28 | $9.20M 10-K · filed 2012-02-28 | |
| 2009-09-30 | $2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $6.18M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | $3.22M 10-Q · filed 2010-07-28 | |||
| 2008-12-31 | $3.64M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |